Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,493 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
Third-line chemotherapy in small-cell lung cancer: an international analysis.
Simos D, Sajjady G, Sergi M, Liew MS, Califano R, Ho C, Leighl N, White S, Summers Y, Petrcich W, Wheatley-Price P. Simos D, et al. Among authors: white s. Clin Lung Cancer. 2014 Mar;15(2):110-8. doi: 10.1016/j.cllc.2013.11.003. Epub 2013 Nov 14. Clin Lung Cancer. 2014. PMID: 24365050
Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC.
Michael M, White SC, Abdi E, Nott L, Clingan P, Zimet A, Button P, Gregory D, Solomon B, Dobrovic A, Do H, Clarke S. Michael M, et al. Among authors: white sc. Asia Pac J Clin Oncol. 2015 Mar;11(1):4-14. doi: 10.1111/ajco.12178. Epub 2014 Feb 27. Asia Pac J Clin Oncol. 2015. PMID: 24575793 Clinical Trial.
The impact and indications for Oncotype DX on adjuvant treatment recommendations when third-party funding is unavailable.
Chin-Lenn L, De Boer RH, Segelov E, Marx GM, Hughes TM, McCarthy NJ, White SC, Foo SS, Rutovitz JJ, Della-Fiorentina S, Jennens R, Antill YC, Tsoi D, Cronk MF, Lombard JM, Kiely BE, Chirgwin JH, Gorelik A, Mann GB. Chin-Lenn L, et al. Among authors: white sc. Asia Pac J Clin Oncol. 2018 Dec;14(6):410-416. doi: 10.1111/ajco.13075. Epub 2018 Sep 30. Asia Pac J Clin Oncol. 2018. PMID: 30270527
6,493 results